TrialMalaria journal2023

Randomized, open-label, phase 2a study to evaluate the contribution of artefenomel to the clinical and parasiticidal activity of artefenomel plus ferroquine in African patients with uncomplicated Plasmodium falciparum malaria.

Adama Gansane et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.